Aripiprazole is a unique atypical antipsychotic drug with an excellent side-effect profile presumed, in part, to be due to lack of typical D 2 dopamine receptor antagonist properties. Whether aripiprazole is a typical D 2 partial agonist, or a functionally selective D 2 ligand, remains controversial (eg D 2 -mediated inhibition of adenylate cyclase is system dependent; aripiprazole antagonizes D 2 receptormediated G-protein-coupled inwardly rectifying potassium channels and guanosine triphosphate nucleotide (GTP)gS coupling). The current study examined the D 2L receptor binding properties of aripiprazole, as well as the effects of the drug on three downstream D 2 receptor-mediated functional effectors: mitogen-activated protein kinase (MAPK) phosphorylation, potentiation of arachidonic acid (AA) release, and D 2 receptor internalization. Unlike quinpirole (a full D 2 agonist) or (À)3PPP (S(À)-3-(3-hydroxyphenyl)-N-propylpiperidine hydrochloride, a D 2 partial agonist), the apparent D 2 affinity of aripiprazole was not decreased significantly by GTP. Moreover, full or partial agonists are expected to have Hill slopes o1.0, yet that of aripiprazole was significantly 41.0. Whereas aripiprazole partially activated both the MAPK and AA pathways, its potency vs MAPK phosphorylation was much lower relative to potencies in assays either of AA release or inhibition of cyclic adenosine 3 0 ,5 0 -cyclic monophosphate accumulation. In addition, unlike typical agonists, neither aripiprazole nor (À)3PPP produced significant internalization of the D 2L receptor. These data are clear evidence that aripiprazole affects D 2L -mediated signaling pathways in a differential manner. The results are consistent with the hypothesis that aripiprazole is a functionally selective D 2 ligand rather than a simple partial agonist. Such data may be useful in understanding the novel clinical actions of this drug.
INTRODUCTION
Traditional pharmacology posits that a single compound acting through a single receptor will cause a single type of functional response (either full, partial or inverse agonism, or antagonism) for all effector pathways associated with that receptor and its milieu. Accordingly, compounds have been categorized by their 'intrinsic efficacy', often defined by the ability of a ligand to modulate receptor-mediated adenylate cyclase (AC) activity. There is increasing evidence, however, that many ligands do not conform to such a rigid definition of function. In fact, recent observations have led to a growing acceptance of the idea that one ligand, while acting on a specific receptor subtype, can have multiple intrinsic activities depending upon the effectors being examined and the model being employed Simmons, 2005) .
For example, we have shown previously that a number of dopamine D 2 ligands exhibit functionally selective profiles Mottola et al, 2002; Gay et al, 2004) . Further evidence for the ability of ligands to activate G-protein-coupled receptor (GPCR)-mediated effectors differentially has been illustrated in serotonin 5-HT 2A and 5-HT 2C (Berg et al, 1998; Kurrasch-Orbaugh et al, 2003) , a 2A -adrenergic Kukkonen et al, 2001) , b 2 -adrenergic (Ghanouni et al, 2001) , cannabinoid CB1 (Glass and Northup, 1999) , m-opioid (Allouche et al, 1999) , and the oxytocin (Reversi et al, 2005) receptor expression systems, among others, effectively illustrating functional selectivity as a universal mechanism of GPCR effector regulation. It is also important to point out that functional selectivity is not an epiphenomenon of a specific receptor expression system, as all of the above observations were made in a number of different physiological models. This mechanism may be relevant to topical issues in neuropsychopharmacology.
Dysfunctional dopaminergic neurotransmission is considered a primary mechanism of schizophrenic symptomology (Kapur and Remington, 2001) , indeed, the early pharmacotherapy for schizophrenia was based on serendipitous discovery of drugs that turned out to be dopamine receptor antagonists (Carlsson, 1964) . Until recently, all of the antipsychotic drugs (APDs), whether 'typical' or 'atypical', or whether of high or low affinity, have been functional D 2 antagonists (Miyamoto et al, 2000; Davies et al, 2004; Maudsley et al, 2005) . A clear exception to this, however, is the recently approved compound aripiprazole (Abilify). The unique pharmacology of this compound first was demonstrated in models that showed aripiprazole-activated effectors associated with presynaptic D 2 autoreceptors, whereas it antagonized D 2 postsynaptic receptor-mediated effects (Kikuchi et al, 1995) . Aripiprazole partially activated D 2 receptor-mediated inhibition of cyclic adenosine 3 0 ,5 0 -cyclic monophosphate (cAMP) accumulation, although this action was system specific (Lawler et al, 1999; Shapiro et al, 2003) . It was suggested that aripiprazole appeared to activate D 2 receptor-mediated effectors differentially, and could be termed a D 2 functionally selective drug (Lawler et al, 1999; Shapiro et al, 2003) . Conversely, Burris et al (2002) have proposed that the unique properties of aripiprazole result solely from its partial agonist properties.
The potential of partial D 2 agonists as a novel treatment of schizophrenia was based in large part on data showing that apomorphine, a high-affinity D 2 dopamine receptor agonist, could preferentially activate D 2 autoreceptors at low doses (Tamminga et al, 1978; Roth, 1979) . It was hypothesized that a D 2 partial agonist might attenuate the activity of hyperactive mesolimbic neurons, and possibly increase neurotransmission in neurons where there was a deficit of activity (ie mesocortical neurons related to working memory). Presumably such compounds also would induce minimal extrapyramidal side effects (and tardive dyskinesia) that are associated with the receptor blockade caused by typical APDs. The potent D 2 -like receptorselective agonist N-propylnorapomorphine (Tamminga et al, 1986) and (À)3PPP (S(À)-3-(3-hydroxyphenyl)-Npropylpiperidine hydrochloride, a D 2 receptor partial agonist) thus seemed to have antipsychotic potential, although patients quickly lost beneficial effects of these agonists rather than having increased efficacy with time as with APDs (Clark et al, 1982; Tamminga et al, 1992; Lahti et al, 1998) . For these reasons, there was a great deal of interest in aripiprazole based on the suggestion that it was the long-anticipated D 2 partial agonist (Lawler et al, 1999; Burris et al, 2002; Shapiro et al, 2003) . In the process, the idea of functional selectivity (Lawler et al, 1999) , despite additional support for this mechanism (Shapiro et al, 2003) , has been dismissed by many authoritative sources (Stahl, 2001; Tamminga, 2002; Lieberman, 2004) .
Previous work has examined functional effects of aripiprazole at D 2 -regulated AC and receptor-regulated potassium channels (Lawler et al, 1999; Burris et al, 2002; Shapiro et al, 2003) . The current study extended this by examining the binding characteristics of aripiprazole at the low and normal affinity states of the dopamine D 2 receptor, as well as the effects of the drug on D 2L receptor-mediated phosphorylation of mitogen-activated protein kinase (MAPK), potentiation of arachidonic acid (AA) release (Missale et al, 1998) , and ligand-induced D 2 receptor internalization.
MATERIALS AND METHODS

Materials
The following were generously donated to this study: aripiprazole (OPC-14597) [5,6,8,9,11,12,13,14- 
Cells and Membranes
The Chinese hamster ovary cells (CHO)-hD 2L cells are a stable line originally obtained from Dr Tony Sandrasagra (Aventis, Bridgewater, NJ). CHO-hD 2L cells were maintained in Ham's F-12 medium supplemented with 10% FBS, 100 U/ ml penicillin, 100 mg/ml streptomycin, and 500 mg/ml G418 at 371C and 5.0% CO 2 . CHO-hD 2L cells were grown to confluence in 75-cm 2 flasks. A measure of 5 ml of cold phosphate-buffered saline was used per flask to rinse the cells, after which 5 ml of lysis buffer (2 mM HEPES, 2 mM EDTA, 1 mM dithiothreitol, 1 mg/ml pepstatin A, 0.5 mg/ml leupeptin, and 10 mg/ml PMSF, pH 7.4 with HCl) was added to each flask. Human embryonic kidney cells (HEK)-FLAG-D 2L cells were also grown and handled in a similar manner as the CHO-hD 2L cells. Following 10-20 min of incubation at 41C, the cells were scraped and collected. The cell suspension was homogenized with three strokes in a Wheaton glass homogenizer and centrifuged at 30 000g for 20 min. The resulting supernatant was discarded, the pellet resuspended in storage buffer (50 mM HEPES, 0.32 M sucrose, 1 mg/ml pepstatin A, 0.5 mg/ml leupeptin, and 10 mg/ml PMSF, pH 7.4 with NaOH) at approximately 1 mg protein/ml, homogenized again, and aliquoted into 1-ml microcentrifuge tubes. The cell membranes then were frozen, and stored at À801C until further use. Measurements of phosphorylated MAPK were made using a published protocol (Versteeg et al, 2000) . CHO cells (both wild type and those transfected with the human D 2L receptor) were seeded in 96-well plates in Ham's F-12 media (10% FBS) at 50 000 cells/cm 2 and allowed to grow at 371C and 5% CO 2 for 48 h. Cells were serum starved for 6 h prior to stimulation, after which appropriate drugs were added to each well at a volume of 100 ml for 10 min. The reaction was terminated and cells fixed by aspirating each well and adding 100 ml of 4% formaldehyde PBS solution for 20 min. Cells were washed three times with 100 ml wash buffer (0.1% Triton X-100/PBS solution), followed by a 20 min incubation with 0.6% H 2 O 2 Triton/PBS solution to quench endogenous peroxidases. After washing the cells three times again with wash buffer, and after a 1 h incubation with 10% BSA in Triton/PBS solution (to block nonspecific antibody binding), cells were incubated overnight (about 12 h) with a 1:250 dilution of PhosphoPlus s p44/42 11 antibody in the Triton/PBS solution (100 ml) containing 5% BSA at 41C. Cells were washed three times with wash buffer for 5 min and incubated with 100 ml HRPconjugated goat anti-rabbit 21 antibody (1:100 dilution) with 5% BSA at room temperature for 1 h. Again, cells were washed three times with wash buffer for 5 min, and then twice with PBS. Cells were then incubated with 50 ml of an o-phenylenediamine (OPD) solution (0.4 mg/ml OPD, 17.8 mg/ml Na 2 HPO 4 Á 7H 2 O, 7.3 mg/ml citric acid and 0.015% H 2 O 2 ) for 15 min at room temperature in the dark. The reaction was terminated by the addition of 25 ml of 1 M H 2 SO 4 , and the well-solution analyzed spectrophotometrically (using the Vmax Kinetic Microplate Reader from Molecular Devices) at absorbance wavelengths A 490 -A 650 .
Saturation and Competition Binding
AA Release Assay
Measurements of phospholipase A 2 (PLA 2 ) AA release were made by modifying a protocol described by Berg et al (1996) . CHO-K1 cells (both wild type and those transfected with the human D 2L receptor) were seeded in 24-well plates in Ham's F-12 media (10% FBS) at 50 000 cells/well and allowed to grow at 371C and 5% CO 2 for 24 h. A measure of 500 ml of serum-free Ham's complete media containing 0.5 mCi/ml [5,6,8,9,11,12,14,15- 3 H]AA was added to wells, after which cells were preincubated for 5 h. Cells were then washed three times for 5 min with Hank's balanced salt solution (HBSS) containing 0.5% fatty acid-free BSA and appropriate enzyme inhibitors and antagonists (500 ml/well/ wash). Following the washes, the cells were incubated for 15 min with appropriate agonists with or without ATP dissolved in the HBSS/BSA (1 ml/well). Three 200 ml sample aliquots were taken from each well and the radioactivity of the samples was counted using liquid scintillation spectrometer techniques.
Epifluorescence Microscopy
HEK293 cells had been stably transfected with FLAG epitope-tagged D 2L receptors, and their functional integrity confirmed previously (Vickery and von Zastrow, 1999) . As described previously (Vargas and von Zastrow, 2004) , these cells were plated on glass coverslips and the surface receptors specifically labeled using 3 mg/ml anti-FLAG M1 monoclonal antibody. Cells were exposed to the indicated ligands at 371C for 30 min, fixed using 4% formaldehyde dissolved in PBS, and then labeled receptors were detected by secondary incubation with Cy3-conjugated goat antimouse antibody (1:1000 dilution). Specimens were visualized by confocal fluorescence microscopy using a Zeiss LSM510 microscope fitted with a Zeiss 63XNA1.4 objective operated in single photon mode with standard filter sets and standard (1Airy disc) pinhole. Metamorph software (Molecular Devices) was employed to count internalized vesicles in 20 random cells per condition per coverslip, with three to six coverslips representing each condition.
Data Analysis
Except where noted, data are expressed as means7SEM. Data from receptor saturation isotherms was analyzed using nonlinear regression with a one-site hyperbolic model, and the data converted to K D and B max . The receptor competition data were analyzed by nonlinear regression using a sigmoidal model with variable slope, yielding IC 50 (concentration inhibiting 50% of total binding IC 50 ) and Hill slopes values. The IC 50 's were corrected for radioligand concentration and converted to concentration corrected IC 50 (apparent affinity constant) when Hill coefficient (n H )a1.0 (K 0.5 ) values using the Cheng-Prusoff formula for a bimolecular competition model (Cheng and Prusoff, 1973) . Changes in affinity in the competition assays were tested for significance by performing a one-way analysis of variance (ANOVA), followed by a Tukey-Kramer multiple comparisons post hoc analysis. Functional dose-response curves also were analyzed by nonlinear regression using Prism 4.0's sigmoidal equation with variable slope in order to determine estimates of intrinsic activity and apparent potency. Differences in potency values between the MAPK and AA release effectors for each agonist was analyzed with an unpaired two-sided t-test, whereas differences among the drug groups were assessed by ANOVA. Significant ANOVA results were followed by the appropriate (Bonferonni's or Dunnett's) post hoc analysis, again performed using Prism 4.0. ]N-methylspiperone binding was carried out using CHO-hD 2L cell membranes both in the absence and presence of 600 mM GTP. The resulting competition curves were best fitted to a variable slope binding model, from which their apparent affinities (K 0.5 ) and Hill slope values (n H ) were derived (Table 1) . ANOVA was utilized to evaluate shifts in affinity in the presence of GTP. Both quinpirole and (À)3PPP demonstrated significant loss of affinity in the presence of GTP, as would be expected of a GPCR agonist, and is illustrated by a rightward shift of their competition curves (Figure 1a and b). They also display Hill slope values typical of agonists (n H o1) in the absence of GTP. Conversely, aripiprazole failed to demonstrate a significant change in affinity (Table 1 and Figure 1c) . It was observed, however, that there was a small, but consistent, shift in every experiment. A more stringent analysis (paired one-tailed t-test) was employed, and it determined that the slight shifts were indeed significant. It appears, therefore, that the binding of aripiprazole is slightly affected by the G-protein-coupled state of the D 2L receptor, and is unique among the D 2 receptor agonists studied. Moreover, the Hill slope for aripiprazole (n H 41) does not correspond with what would be expected of either an agonist or antagonist following the law of mass action. There appears to be a suggestion of positive cooperativity that affects the binding of aripiprazole to the D 2L receptor. As expected, the apparent affinity of the typical APD and known D 2 receptor antagonist, haloperidol, was not affected by GTP (Figure 1d) , and its Hill slope value in the absence of GTP corresponds well with what would be expected of an antagonist (n H B1).
RESULTS
Aripiprazole Activation of D 2 Receptor-Mediated MAPK Phosphorylation
To confirm that the D 2 receptor-mediated activation of the MAPK pathway was indeed regulated by MEK, the maximal MAPK phosphorylation by quinpirole was shown to be fully inhibited by 50 mM PD98059, an inhibitor of MEK (data not shown). Quinpirole was found to exhibit slightly higher intrinsic activity than the endogenous agonist dopamine, while (À)3PPP and aripiprazole displayed about 60 and 50% of the activity of quinpirole, respectively (Figure 2) . The rank order of potency among the four compounds was dopamine ¼ quinpirole4(À)3PPP4aripiprazole. Haloperidol was able to fully inhibit maximally stimulating concentrations of all four agonists, further indicating that the pathway is D 2 receptor mediated. It was also confirmed that aripiprazole failed to promote the phosphorylation of MAPK in the untransfected CHO-K1 cell line (Figure 3) . The other atypical APDs (clozapine, olanzapine, amisulpride, and melperone) showed no significant intrinsic activity for MAPK phosphorylation, and largely inhibited a maximally stimulating concentration (100 nM) of quinpirole (Figure 3) . The inability of clozapine, olanzapine, and melperone to inhibit the MAPK effector pathway fully can be attributed to inadequate fractional occupancy at concentrations used rather than low intrinsic partial agonism.
Aripiprazole Promotes the D 2 Receptor-Mediated Potentiation of AA Release
There has been much debate on the pathway mechanism of GPCR-mediated AA release, and it appears that the mechanism may vary somewhat among different receptors and may be dependent on multiple signaling pathways . We used staurosporine (a pan-kinase inhibitor), PD98059 (an MEK inhibitor), and Ro318220 (a protein kinase C (PKC) inhibitor), in the presence of 10 mM quinpirole. Staurosporine and PD98059 both inhibited AA release (54 and 73%, respectively), but did not cause an additive change when cells were treated with both (53% inhibition). Analysis by ANOVA with Bonferroni's post hoc test demonstrated that there was no significant difference among these three inhibitor treatment scenarios (Figure 4) . Treatment with Ro318220 failed to affect the intrinsic activity of quinpirole, indicating that the activity of PKC does not appear to influence D 2L -meditated potentiation of AA release in this CHO cell line. Our observations indicate that, at least in the CHO cell line, the potentiation of AA release as regulated by hD 2L receptor activation is dependent on multiple pathways. Mepacrine (100 mM) fully inhibited the quinpirole potentiation of AA release, whereas melittin was found to stimulate the release of AA (data not To evaluate the intrinsic activity of haloperidol (Hal), amisulpiride (Ami), clozapine (Clz), melperone (Mel), olanzapine (Ola), and aripiprazole (Ari), the following design was used. The open bars show the intrinsic activity of each compound alone, where the compounds were used at a concentration of 10 mM. The antagonism study (black bars) also used this same concentration of each potential antagonist vs a challenge concentration of quinpirole (100 nM except in the case of aripiprazole where 10 mM was used (see Results)). None of the compounds except aripiprazole caused a significant response alone. All of the atypical APDs except aripiprazole were able to block quinpirole stimulation to a similar degree as haloperidol. Inset: The degree of MAPK stimulation elicited by aripiprazole (Ari) (closed bars) relative to basal levels of MAPK activity (open bars) in the untransfected parental CHO-K1 cell line. Data are expressed as a percentage of the maximal stimulation of quinpirole over basal phosphorylation. Each value represents the mean7SEM of three independent experiments conducted in triplicate.
shown), suggesting the role of PLA 2 in the hD 2L receptormediated potentiation of the AA release signaling pathway. Similar to the MAPK effector studies, all four of the D 2 ligands were able to potentiate the release of AA to varying degrees. Both quinpirole and dopamine fully stimulated AA release, while aripiprazole and (À)3PPP demonstrated partial activity of the effector pathway ( Figure 5 ). The rank order of potency among the four compounds was aripiprazole4dopamine ¼ quinpirole4(À)3PPP. Of interest, however, were the potencies that characterized the activities of the compounds for the pathway (Table 2) . While the three typical agonists had potencies for AA release fairly congruent with those observed for the MAPK pathway, aripiprazole illustrated a 20-fold higher potency for the D 2 -mediated potentiation of AA release than MAPK phosphorylation. Further analysis of the potency differences between MAPK and AA release experiments for each drug using ANOVA (followed by a Dunnett's post hoc multiple comparisons test) illustrated that only aripiprazole exhibited a significant potency shift relative to that of quinpirole (po0.01). Incidentally, the EC 50 of aripiprazole for AA release is similar to the potency of aripiprazole reported for D 2 receptor-mediated inhibition of AC (Lawler et al, 1999; Burris et al, 2002; Shapiro et al, 2003) . As with the MAPK studies, haloperidol was able to fully inhibit the ability of all four compounds to potentiate AA release, verifying D 2L receptor activation as the means by which these ligands were able to exact their influence on the pathway. It was also observed that aripiprazole was unable to promote the release of AA in the parental CHO-K1 cell line, confirming that the activity of aripiprazole at this effector is specific to the transfected D 2L receptor. Finally, none of the other atypical APDs examined illustrated agonist activity for the AA release pathway (Figure 6 ).
Aripiprazole Fails to Stimulate Internalization of the FLAG-Tagged hD 2L Receptor
It was originally thought a compound that displayed an agonist functional profile would induce some degree of receptor endocytosis, and that competitive antagonists, by their very nature, would be unable to provoke such a response (Ferguson, 2001 ). More recent evidence indicates, however, that certain antagonists can internalize certain receptors (Berry et al, 1996; Roettger et al, 1997) , and that the internalization process can be agonist-specific depending on the cellular milieu specific to that receptor expression system (Ryman-Rasmussen et al, 2005) . These observations complement the fundamentals of functional selectivity, which state that the intrinsic activity of a ligand Functional data represent the means7SEM (in nM) of three to five independent experiments. Significant potency shifts between the functional end points among the compounds was determined by ANOVA followed by a Dunnett's multiple comparisons post hoc analysis with each compound's mean shift difference compared to that of quinpirole (**po0.01, with all other comparisons having p40.05). See Materials and methods for further details.
is dependent on the pathway being examined and the model around which the investigation revolves. Thus, the study of the ability of a ligand to stimulate receptor internalization has been utilized to understand this aspect of the functional profile of many GPCR ligands. Utilizing HEK293-fD 2L cells (B max ¼ 1.5070.26 pmol receptor/mg protein) and epifluorescent microscopy techniques, we were able to observe a pronounced dopamine-induced increase in the internalization of the FLAG-tagged D 2L receptors relative to basal levels (Figure 7a and b) . Neither aripiprazole, nor the D 2 partial agonist (À)3PPP, however, were able to elicit a detectable endocytotic response relative to basal levels (Figure 7c and d) . Quantification of these results is shown in Figure 8 .
DISCUSSION
Pharmacotherapy for the treatment of schizophrenia has utilized several strategies over the past fives decades, although the pharmacological mechanism common to all successful drugs is the antagonism of dopamine D 2 receptors (Kapur and Mamo, 2003) . The unique pharmacology of aripiprazole, a drug having both partial agonist and antagonist activity at D 2 receptor functions depending on the end point under study, suggests that functionally selective ligands may provide a new arena for the development of novel therapeutics for psychoses and other disorders (Miyamoto et al, 2000; Davies et al, 2004; Maudsley et al, 2005) . The current study was designed to shed further light on the question of whether the D 2 activity of aripiprazole is simple partial agonism or a case of ligand-induced differential signaling. To further investigate this issue, the D 2 receptor-mediated signaling profile of aripiprazole was compared to several other atypical APDs and to both a full and partial agonist, by investigating effectors that, to date, had been used infrequently to characterize APD pharmacology. First, the apparent affinity of the D 2 receptor ligands was determined in CHO cells stably expressing the hD 2L receptor. The rank order of apparent affinities was similar to what has been reported previously (haloperidol4aripi-prazole4quinpirole4(À)3PPP). Agonists for GPCR receptors are expected to produce competition isotherms that shift to the right in the presence of guanine nucleotides (Lefkowitz et al, 1978) , a phenomenon clearly illustrated by the current quinpirole and (À)3PPP binding data. Although GTP caused a consistent shift in the aripiprazole competition curves, this effect was very small, and was statistically significant only when utilizing a one-sided paired t-test. Conversely, quinpirole and (À)3PPP, but not haloperidol, caused a larger shift in affinity and Hill slope (see Table 1 ). These data with aripiprazole may reconcile with the previously published GTPgS binding data in which aripiprazole was found to be a pure antagonist of D 2 receptormediated GTPgS release in CHO-hD 2L membranes (Shapiro et al, 2003) .
Also of interest were Hill slopes (n H ) for aripiprazole that were greater than 1.0. A Hill slope less than one is often considered a reflection of the ability of a ligand to bind to G protein-precoupled receptors with a higher affinity than uncoupled receptors. Thus, antagonists tend to have Hill slope values close to one since they fail to differentiate between the precoupled and uncoupled receptor populations, thereby obeying the general law of mass action for single site competition. As expected, both the typical full and partial agonists quinpirole and (À)3PPP had different affinities for these populations of hD 2L receptors based on the changes in competition curves seen in response to GTP. The competition isotherm of haloperidol fits the binding profile of a typical antagonist (ie it both lacks a GTP shift and has an n H value close to one). The steep slope for aripiprazole, as well as a small but significant GTP effect, suggests that additional mechanisms are involved. One hypothesis for such observations is that certain ligands may promote positive cooperativity of dimerized or oligomerized receptor (Lavoie and Hebert, 2003) , or by allosteric interaction with a secondary domain of the receptor or another protein present in the microdomain (eg a scaffolding or accessory/chaperone protein). It is plausible that the receptor-receptor or receptor-protein interaction that imparts this positive cooperativity only occurs upon the induction of specific receptor conformations. Whatever the case, the unique receptor binding characteristic of aripiprazole is not exclusive to the CHO-hD 2L stable cell model, as similar observation was made in brain tissue (Lawler et al, 1999) . Further study is necessary to understand the underlying mechanism.
It is known that D 2 receptor agonists can stimulate the MAPK pathway in stable C6 and CHO-transfected cells (Luo et al, 1998; Choi et al, 1999) . By modifying an ELISA highthroughput assay (Versteeg et al, 2000) , we were able to determine intrinsic activities and potencies for the D 2 ligands we studied. The intrinsic activity of aripiprazole correlates well with its reported activity for the D 2L -mediated inhibition of cAMP accumulation (Lawler et al, 1999; Burris et al, 2002; Shapiro et al, 2003) . The major point of interest, however, lies in the low potency of aripiprazole for the MAPK effector pathway. With the exception of aripiprazole, prior cAMP inhibition EC 50 data for all compounds correspond fairly well with the MAPK potencies reported in this study (Wilson et al, 2001; Burris et al, 2002; Gay et al, 2004) .
The biosynthesis and regulation of prostaglandin-like compounds by catecholamines has been of interest for several years (Levine and Moskowitz, 1979) . The ability of the D 2 receptor to mediate the release and metabolism of AA from the intercellular membrane is known (Piomelli et al, 1991; Felder et al, 1991) , and although the exact mechanism is not well understood, there has been much discussion as to how it might be regulated by other signaling effectors, most notably AC, MAPK, and PKC (see Chakraborti, 2003 for a review). There appears to be significant evidence that the GPCR-mediated release of AA, in fact, may be regulated by more than just one pathway, and both the MAPK and PKC effectors appear to play significant roles in AA release . For this study, it was vital to demonstrate that the release of AA was not solely dependent on a D 2 receptor-mediated effector already under study (ie MAPK phosphorylation). Neither staurosporine nor PD98059 was able to inhibit the D 2 receptor-mediated release of AA fully. This demonstrates a significant degree of independence of AA release from modulation by MAPK signaling pathways. In addition, PKC inhibition had no effect on the D 2 receptor regulation of this pathway. This independence of D 2L -mediated AA release from PKC indicates that this cell line differs from some others .
The intrinsic activity (E max ) of aripiprazole for AA release proved to be similar to its ability to stimulate the phosphorylation of MAPK (Figures 3 and 6) , although its potency for the former end point clearly paralleled its reported potency for the D 2 receptor-mediated inhibition of cAMP accumulation (Lawler et al, 1999; Burris et al, 2002; Shapiro et al, 2003) . This method of comparison assessment is valid because the intrinsic activity of aripiprazole was similar at both MAPK and AA release, and therefore the direct comparison of ED 50 's is equivalent to the direct comparison of ED 50 /E max . Unlike aripiprazole, the D 2 agonists quinpirole, dopamine, and (À)3PPP all displayed potencies for the release of AA similar to that for the phosphorylation of MAPK. In fact, the difference in the potencies of aripiprazole between the two effectors is over 20-fold (Figure 9 ). This disparity is especially striking in context with the observation hat other functionally selective D 2L ligands (eg DHX, DNS, RNPA) also have demonstrated significant potency differences among D 2 receptor effectors .
The intrinsic activity of aripiprazole for the D 2L receptormediated phosphorylation of MAPK may not be of significant physiological relevance since the cell system used had a high level of receptor expression (B max B6 pmol/ mg protein). It is well documented that, in systems with high receptor reserve, compounds with low intrinsic activity can mimic compounds with higher intrinsic activities for that effector system (eg Watts et al, 1995) . This notion, coupled with preliminary experiments that utilized the nonspecific, irreversible protein binding compound EEDQ to reduce receptor levels (data not shown), suggests that D 2 modulation of MAPK may not be an effector pathway affected by aripiprazole in physiologically relevant systems. It underscores the importance of using, when available, cell lines that mirror as much as feasible those cells expressing the receptor under study in situ.
The model commonly used to illustrate GPCR internalization describes an agonist-receptor interaction that promotes receptor phosphorylation via a GRK or other kinase, with subsequent arrestin binding and receptor sequestration via clathrin-coated pits (von Zastrow, 2003) . Not all GPCRs follow the same mechanism of internalization, and the intracellular loops of a receptor, as well as the local cellular milieu, play an important role in the mechanism of endocytosis (Ferguson, 2001) . D 2 receptors have been shown to internalize in a manner dependent upon GRKs, clathrin, and dynamin (Kim et al, 2001) , although dynamin-independent internalization can be observed in cells expressing GRKs at lower levels (Vickery and von Zastrow, 1999) . Studies in an HEK293-fD 2L system showed that the D 2L receptor displays both basal (constitutive) and dopamine-induced internalization, and that haloperidol can block dopamine-induced, but not constitutive, internalization (Vickery and von Zastrow, 1999) . Our study indicates that neither aripiprazole nor the typical partial agonist (À)3PPP induce a significant degree of internalization relative to basal levels, indicating that either D 2 ligands with low intrinsic activity fail to produce D 2 receptor internalization or that these two compounds are unique in their promotion of receptor conformations that cannot be phosphorylated by the appropriate kinases. Although (À)3PPP can desensitize the D 2 receptor (Lahti et al, 1998) , it is clear that this does not necessarily predict internalization (Lewis et al, 1998; Ryman-Rasmussen et al, 2005) . Further experiments are needed to determine whether D 2 receptor internalization is a product unique to ligands that are full agonists, or if aripiprazole and (À)3PPP are unique in their inability to internalize the D 2 receptor.
Some of the most efficacious atypical APDs (clozapine, amisulpride, olanzapine), as well as a compound considered to have good atypical APD potential (melperone), were also studied. Vanhauwe et al (2000) had reported that these compounds should be considered as D 2 receptor antagonists based on their inhibition of AC, although melperone was not studied by them. We hypothesized that a study of their regulation of D 2L function might reveal functional characteristics that explained some of their behavioral atypicality. The current study demonstrates that none of these four atypicals have any D 2L intrinsic activity for either MAPK phosphorylation or AA release, and all four blocked the activity of quinpirole for both endpoints. Thus, these data suggest that neither the efficacy nor low EPS of these compounds involves functional selectivity.
In conclusion, the promise of even more effective D 2 partial agonists has been widely proposed based on the success of aripiprazole (Burris et al, 2002; Lieberman, 2004; Bolonna and Kerwin, 2005) . Conversely, we have suggested that functional selectivity at D 2 receptors, probably combined with actions at nondopamine receptors (Lawler et al, 1999; Shapiro et al, 2003) , is the more likely mechanism responsible for the atypicality of this drug. It seems clear to us that the available evidence (including the current work) supports only the latter hypothesis. No other D 2 partial agonist has shown similar therapeutic promise to aripiprazole. More importantly, even those who have advocated for simple partial agonism (Burris et al, 2002) now have shown cell-dependent differences in the intrinsic activity of aripiprazole (Tadori et al, 2005) . The most parsimonious way to reconcile the available data is accept the hypothesis that the pattern of D 2 functional selectivity, and/or combined with actions at other receptors systems (eg 5-HT 1A , 5-HT 2C , etc), mediate the novel actions of aripiprazole, rather than simple partial agonism. More detailed understanding of these mechanisms may help find a drug with an improved clinical profile. Figure 9 Relative potency of D 2L ligands for the potentiation of AA release and phosphorylation of MAPK. Ligands with similar potency for both AA release and MAPK phosphorylation have a log (fold change) of close to zero (quinpirole (QUIN) and (À)3PPP), whereas compounds having decreased potency for MAPK phosphorylation relative to AA release display a negative change (aripiprazole (ARI)), and ligands with an increased potency for MAPK phosphorylation compared to AA release display a slight positive change (dopamine (DA)). Data illustrated for each ligand are expressed as the log of EC 50 (nM) for MAPK phosphorylation divided by their respective log of EC 50 value for AA release.
